Failure of the treatment or acquired resistance are in part attributable to intratumoral heterogeneity not only of cancer cells but of TME populations, particularly in response to BRAF and anti-PD1 therapy [36,37,38,39]. The gene discussed is BRAF; the disease is cancer.